FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation

[FDA]

On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US Inc.) for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.


Baca selengkapnya di : http://www.fda.gov...